Response to comment on "Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics".
Bovijn J., Krebs K., Chen C-Y., Boxall R., Censin JC., Ferreira T., Pulit SL., Glastonbury CA., Laber S., Millwood IY., Lin K., Li L., Chen Z., Milani L., Smith GD., Walters RG., Mägi R., Neale BM., Lindgren CM., Holmes MV.